Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Alnylam Pharmaceuticals Inc (ALNY)

776 + Investors. Track Smart Money conviction in ALNY. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
2Q ▼
Buyers last Q
52%

Smart Money Signals — ALNY

Based on 789 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds reduced or closed their ALNY positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 93% of 3.0Y peak

93% of all-time peak
789 funds currently hold this stock — 93% of the 3.0-year high of 847 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🚀

Fast accumulation — +21% more funds vs a year ago

fund count last 6Q
+136 new funds entered over the past year (+21% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 52% buying

424 buying386 selling
Last quarter: 424 funds bought or added vs 386 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-12 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 218 → 170 → 108 → 96. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

54% of holders stayed for 2+ years

■ 54% conviction (2yr+) ■ 25% medium ■ 21% new
426 out of 789 hedge funds have held ALNY for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +53%, value -3%

Value
-2%
Shares
+53%
Last quarter: funds added +53% more shares while total portfolio value only changed -3%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📊

Peak discovery — momentum slowing

102 → 218 → 170 → 108 → 96 new funds/Q
New funds entering each quarter: 218 → 170 → 108 → 96. ALNY is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 60% veterans vs 26% newcomers

■ 60% veterans ■ 14% 1-2yr ■ 26% new
Entry-cohort mix of 820 holders: 492 (60%) are 2+ year veterans, 114 entered 1–2 years ago, and 214 (26%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 72% AUM from top-100 funds

72% from top-100 AUM funds
71 of 783 holders are among the 100 largest funds by AUM, controlling 72% of total institutional value in ALNY. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.2
out of 10
Low Exit Risk
Exit risk score 3.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ALNY

In 2026 Q2, 424 hedge funds were net buyers of ALNY (96 opened a new position, 328 added to an existing one), while 386 reduced or exited (287 trimmed, 99 sold completely) — a 52% buyer ratio, indicating a slight buying edge. Net selling has persisted for two consecutive quarters. 72% of total institutional value in ALNY is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 789.

Hedge Fund Ownership: ALNY

How many hedge funds hold ALNY — quarterly history vs. share price
Quarterly hedge fund ownership of ALNY vs. share price

Market Analysis: ALNY

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ALNY

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Alnylam Pharmaceuticals Inc (ALNY) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ALNY has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 77d ago
ALNY
-17.0%
XLV
+5.7%

ALNY outperformed XLV by -22.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 32d ago
ALNY
+9.3%
XLV
+0.2%

Since the filing became public, ALNY outperformed XLV by +9.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

26 top-rated funds 3 high-conviction
Consensus
6.2
/ 10
breadth
×
Elite
3.7
/ 10
conviction
Hedge Fund Positioning: ALNY
776 + Investors

Track Smart Money conviction in ALNY. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 776 792 -2.02%
13F Shares 135M 127M 6.17%
Total Value $38.38B $39.62B -3.11%
New Positions 94 108 -14
Increased Positions 317 318 -1
Closed Positions 104 163 -59
Reduced Positions 273 253 +20
Total Calls 19 17 11.76%
Total Puts 17 17 -
PUT/CALL Ratio 0.89 1.0 Neutral

Statistics: ALNY

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

776 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ALNY. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ALNY holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Davern Capital Partners, LP 5.80% 113,085 $34.0M
2 Prosight Management, LP 5.09% 98,080 $29.5M
3 Deep Track Capital, LP 3.61% 825,000 $248.3M
4 Paradigm Biocapital Advisors LP 2.71% 480,000 $144.5M
5 Rosenblum Silverman Sutton S F Inc /Ca 2.33% 32,172 $9.7M
6 Cannon Global Investment Management, LLC 2.13% 2,500 $753K
7 Orbis Allan Gray Ltd 2.06% 1,987,407 $598.3M
8 683 Capital Management, LLC 1.59% 107,500 $32.4M
9 Parkman Healthcare Partners LLC 1.56% 50,672 $15.3M
10 Sierra Summit Advisors LLC 1.40% 41,684 $12.5M
11 Bronte Capital Management Pty Ltd. 1.14% 35,384 $10.7M
12 Ishara Investments LP 1.13% 5,125 $1.5M
13 Casdin Capital, LLC 1.13% 75,000 $22.6M
14 Polymer Capital Management (HK) LTD 0.99% 64,957 $19.6M
15 Rock Springs Capital Management LP 0.98% 66,750 $20.1M
16 ANTIPODES PARTNERS Ltd 0.90% 163,533 $49.2M
17 Gilder Gagnon Howe & Co LLC 0.84% 269,051 $81.0M
18 Los Angeles Capital Management LLC 0.81% 729,635 $219.6M
19 Tremblant Capital Group 0.80% 92,940 $28.0M
20 Twinbeech Capital LP 0.78% 14,325 $4.3M
21 Longaeva Partners L.P. 0.73% 110,261 $33.2M
22 Virtus Investment Advisers, LLC 0.70% 9,953 $3.0M
23 Baillie Gifford & Co 0.67% 2,439,889 $734.5M
24 Portman Square Capital LLP 0.66% 46,200 $13.9M
25 Privium Fund Management B.V. 0.63% 11,372 $3.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Alnylam Pharmaceuticals Inc (ALNY)

What does the Smart Money Trend signal show for ALNY?

Selling streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds reduced or closed their ALNY positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ALNY?

Slight buying edge — 52% buying: Last quarter: 424 funds bought or added vs 386 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ALNY holders?

Elite ownership — 72% AUM from top-100 funds: 71 of 783 holders are among the 100 largest funds by AUM, controlling 72% of total institutional value in ALNY. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ALNY?

54% of holders stayed for 2+ years: 426 out of 789 hedge funds have held ALNY for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Alnylam Pharmaceuticals Inc (ALNY) following the 2026 Q2 hedge fund 13F filings?

As of today, ALNY has moved +9.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.2% for the XLV sector ETF — an outperformance of +9.1%. Since the quarter end (June 30, 2026), ALNY has gained -17.0% vs +5.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →